

Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notice is available for immediate inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for the notice or to the offices of the Board of Governors. Comments must be received not later than January 10, 1996.

A. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *John Smithhisler*, Las Cruces, New Mexico; to acquire an additional 2.2 percent, for a total of 11.8 percent of the voting shares of Las Cruces B.R.G., Inc., Las Cruces, New Mexico, and thereby indirectly acquire Bank of the Rio Grande, N.A., Las Cruces, New Mexico.

Board of Governors of the Federal Reserve System, December 18, 1995.

Jennifer J. Johnson,

*Deputy Secretary of the Board.*

[FR Doc. 95-31150 Filed 12-21-95; 8:45 am]

BILLING CODE 6210-01-F

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Administration of Children and Families**

**Agency Information Collection Under OMB Review**

*Title:* National Study of Outcomes for Children Placed in Foster Care with Relatives.

*OMB No.:* New.

*Description:* This is a series of interview forms for use with state administrators, case workers, and foster parents in seven states selected for the study. State administrators are the Chief Child Welfare Administrator, the fiscal administrator, and management information system specialist in each state. The National Study of Outcomes for Children Placed in Foster Care with Relatives will be used to describe policies, practices and characteristics regarding placement of children in foster care with relatives; to describe outcomes of children placed in foster care with relatives compared to children placed in non-relative foster care; and to examine the associated costs of relative foster care compared to non-relative foster care.

Under a contract from the Administration on Children, Youth and Families (ACYF), researchers from TransAmerica Systems, Inc., will

conduct the National Study of Outcomes for Children Placed in Foster Care with Relatives. The study is in three phases. Phase I was an initial on-site survey of nine States which make extensive use of relative roster care, which have sufficient and accessible data, and which are willing to participate in the survey. During Phase II, a national study was designed based on results from the nine State survey, with the assistance of a Technical Advisory Panel, consisting of nationally recognized foster care experts; a thorough literature review; and input from organizations with interest in foster children, a national study is designed during Phase II. Phase III will be conducting the national study, analyzing the data, and preparing a final report. This will include in-depth site visits to seven States, purposively sampled from the 34 States that are able to identify whether children are placed with relatives or with non-relatives. State child welfare administrators and workers and foster parents will be selected for in-depth interviews. Additionally, the research team will also extract information from case records and gather demographic data and fiscal information from the States visited.

*Respondents:* 441 (280 foster parents; 161 staff).

Title	Number of respondents	Number of responses per respondent	Average burden per response	Burden hours
Administrator Interview .....	7	1	2	14
Caseworker Interview .....	140	1	1	140
Foster Parent Interview .....	280	1	1	280
Demographic Information Report .....	7	1	1	7
Fiscal Information Report .....	7	1	1	7
<b>Total .....</b>	<b>441</b>	<b>.....</b>	<b>.....</b>	<b>448</b>

*Estimated Total Annual Burden Hours:* 448.

*Additional Information:* Copies of the proposed collection may be obtained by writing to: Reports Clearance Officer, Administration for Children and Families, Department of Health and Human Services, 370 L'Enfant Promenade, S.W., Washington, D.C. 20447.

*OMB Comment:* Consideration will be given to comments and suggestions received within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork

Reduction Project, 725 17th Street, N.W., Washington, D.C. 20503, Attn: Ms. Wendy Taylor.

Dated: December 14, 1995.

Arnold Jacobson,

*Acting ACT Reports Clearance Officer.*

[FR Doc. 95-31184 Filed 12-21-95; 8:45 am]

BILLING CODE 4148-01-M

**Centers for Disease Control and Prevention**

**Citizens Advisory Committee on Public Health Service Activities and Research at Department of Energy (DOE) Sites, Savannah River Site Health Effects Subcommittee; Meeting**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Agency for Toxic Substances and Disease Registry (ATSDR) and the Centers for Disease Control and Prevention (CDC) announce the following meeting.

*Name:* Citizens Advisory Committee on Public Health Service Activities and

Research at DOE Sites: Savannah River Site Health Effect Subcommittee (SRS).

*Times and Dates:* 9 a.m.–5 p.m., January 11, 1996; 9 a.m.–12 noon, January 12, 1996.

*Place:* Hilton—The De Soto, 15 East Liberty Street, Savannah, Georgia 31401, telephone 912/232-9000, FAX 912/232-6018.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 75 people.

*Background:* Under a Memorandum of Understanding (MOU) signed in December 1990 with DOE, the Department of Health and Human Services (HHS) has been given the responsibility and resources for conducting analytic epidemiologic investigations of residents of communities in the vicinity of DOE facilities, workers at DOE facilities, and other persons potentially exposed to radiation or to potential hazards from non-nuclear energy production use. HHS delegated program responsibility to CDC.

In addition, an MOU was signed in October 1990 and renewed in November 1992 between ATSDR and DOE. The MOU delineates the responsibilities and procedures for ATSDR's public health activities at DOE sites required under sections 104, 105, 107, and 120 of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA or "Superfund"). These activities include health consultations and public health assessments at DOE sites listed on, or proposed for, the Superfund National Priorities List and at sites that are the subject of petitions from the public; and other health-related activities such as epidemiologic studies, health surveillance, exposure and disease registries, health education, substance-specific applied research, emergency response, and preparation of toxicological profiles.

*Purpose:* This Subcommittee is charged with providing advice and recommendations to the Director, CDC and the Administrator, ATSDR, regarding community American Indian Tribes, and labor concerns pertaining to CDC's and ATSDR's public health activities and research at respective DOE sites. Activities shall focus on providing a forum for community, American Indian Tribal, and labor interaction and serve as a vehicle for community concern to be expressed as advice and recommendations to CDC and ATSDR.

*Matters to be Discussed:* This Subcommittee will listen to presentations from the Radiological Assessments Corporation, Medical University of South Carolina Cancer Registry, as well as updates on the Savannah River Site Phase II Dose Reconstruction Project findings and implications. Additional agenda items will include: the National Center for Environmental Health (NCEH) activities, the National Institute for Occupational Safety and Health and ATSDR presentations on the progress of current studies, and issues regarding the Committee selection process.

Agenda items are subject to change as priorities dictate.

*Contact Persons for More Information:* Paul G. Renard or Nadine Dickerson, Radiation Studies Branch, Division of Environmental Hazards and Health Effects, NCEH, CDC,

4770 Buford Highway, NE, (F-35), Atlanta, Georgia 30341-3724, telephone 770/488-7040, FAX 770/488-7044.

Dated: December 18, 1995.

Carolyn J. Russell,

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 95-31152 Filed 12-21-95; 8:45 am]

BILLING CODE 4163-18-M

## Food and Drug Administration

### Grassroots Regulatory Partnership Meeting; Southwest Region; Importing Commodities

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of a public meeting.

**SUMMARY:** The Food and Drug Administration (FDA) (Office of Regulatory Affairs, Office of the Southwest Region, and Office of External Affairs) is announcing a free public meeting to discuss ways FDA could regulate imported commodities more efficiently, improve levels of communication with industries and individuals associated with the importation of FDA-regulated commodities, and provide improved levels of consumer protection in connection with imported commodities being shipped into the United States across the United States-Mexico border. This meeting is intended to identify and evaluate opportunities for implementing the President's initiative for a partnership approach between the agency and the people affected by the work of this agency.

**DATES:** The public meeting will be held on Wednesday, January 31, 1996, from 9 a.m. to 12 m.

**ADDRESSES:** The public meeting will be held at the Concourse Clarion Hotel, Oxford Room A and B, 6789 Boeing, El Paso, TX 79926.

**FOR FURTHER INFORMATION CONTACT:** Barbara A. Cain, Food and Drug Administration, 300 East Eight St., rm. B123, Austin, TX 78701, 512-482-5736, or Robert G. Rast, Food and Drug Administration, 9777 Via De La Amistad, rm. 128, San Diego, CA 92173, 619-661-3273.

**SUPPLEMENTARY INFORMATION:** There is no registration fee for this meeting. However, due to space limitations, early registration is recommended. This meeting is intended to assist importers, brokers, and others associated with a wide variety of products being shipped through the southwest and west coast (FDA Southwest and Pacific Regions).

Dated: December 15, 1995.

William K. Hubbard,

*Associate Commissioner for Policy Coordination.*

[FR Doc. 95-31195 Filed 12-21-95; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 95N-0403]

### Drug Export; SURGISCREEN® 0.8 Percent, Reagent Red Blood Cells

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that Ortho Diagnostic Systems, Inc., has filed an application requesting approval for the export of the human biological product SURGISCREEN® 0.8 percent, Reagent Red Blood Cells to Australia, Austria, Belgium, Canada, Denmark, The Federal Republic of Germany, Finland, France, Iceland, Ireland, Italy, Japan, Luxembourg, The Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, and The United Kingdom.

**ADDRESSES:** Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human biological products under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

**FOR FURTHER INFORMATION CONTACT:** Cathy E. Conn, Center for Biologics Evaluation and Research (HFM-610), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-594-2006.

**SUPPLEMENTARY INFORMATION:** The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of human biological products that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the Federal Register within 10 days of the filing of an application for export to facilitate public participation in its